Skip to headlines

BUSINESS

Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

CNBC BusinessFriday, November 6, 2026 at 12:43 PM

RedScroll Brief

The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.

RedScroll Signal

Impact
High
Category
Business
Market relevance
High
Why it matters
Corporate and market moves reprice risk and reveal where power and cash are concentrating. The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%. Investors will watch earnings, rates, and competitive positioning connected to Moderna and Business.

Desk copy

RedScroll Briefing

Extractive editorial brief — not a reprint of the original

What happened

The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.

Why it matters

Corporate and market moves reprice risk and reveal where power and cash are concentrating.

Background

CNBC Business reported on this under business. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.

Timeline

  1. CNBC Business published: Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

  2. Story is in today’s RedScroll edition. Follow the original source for updates.

Economic impact

Investors will watch earnings, rates, and competitive positioning connected to Moderna and Business.

More on

Related stories

Source

CNBC Business

Original reporting by CNBC Business. RedScroll provides an extractive briefing only.